Loading..

Myriad Genetics, Inc. (MYGN) Report Analysis

Corporate Events

Neutral

Myriad Genetics, Inc. Teams Up with Epic to Mak...

2022-06-23 20:05:00

Myriad Genetics, Inc. announced a partnership with Epic to integrate Myriad’s full line of genetic tests with Epic’s expansive network of 600,...

Neutral

Myriad Genetics, Inc. Presents at Goldman Sachs...

2022-06-10 00:52:00

Myriad Genetics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022 01:20 PM. Venue: Terranea Resort, Rancho...

Neutral

Myriad Genetics, Inc. has filed a Shelf Registr...

2022-06-06 00:00:00

Myriad Genetics, Inc. has filed a Shelf Registration in the amount of $37.44 million. Security Name: Common Stock Securities Offered: 2,00...

Negative

Myriad Genetics, Inc. Announces Executive Changes

2022-06-02 20:30:00

On June 2, 2022, the Board of Directors of Myriad Genetics, Inc. designated Natalie Munk, the Company's Chief Accounting Officer, to serve as ...

Positive

Myriad Genetics Showcases Advancements in Preci...

2022-05-26 22:30:00

Myriad Genetics, Inc. will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the ...

Neutral

Myriad Genetics, Inc. Provides Earnings Guidanc...

2022-05-05 13:00:00

Myriad Genetics, Inc. provided earnings guidance for the fiscal year 2022. For the year, the company expects revenue to be in the range of $67...

Negative

Myriad Genetics, Inc. Reports Goodwill and Long...

2022-05-05 13:00:00

Myriad Genetics, Inc. reported goodwill and long-lived asset impairment charges for the first quarter ended March 31, 2022. For the quarter, t...

Neutral

Myriad Genetics, Inc. Expands Partnership with ...

2022-05-03 20:15:00

Myriad Genetics, Inc. announced the expansion of its strategic partnership with Intermountain Precision Genomics to add a new liquid biopsy th...

Neutral

Myriad Genetics, Inc. to Report Q1, 2022 Result...

2022-04-28 20:05:00

Myriad Genetics, Inc. announced that they will report Q1, 2022 results Pre-Market on May 05, 2022

Neutral

Myriad Genetics, Inc., Q1 2022 Earnings Call, M...

2022-04-28 20:05:00

Myriad Genetics, Inc., Q1 2022 Earnings Call, May 05, 2022

Neutral

Embark Veterinary, Inc., Second Annual Canine H...

2022-04-21 13:00:00

Embark Veterinary, Inc., Second Annual Canine Health Summit 2022, Apr 27, 2022 through Apr 28, 2022.

Neutral

Myriad Genetics, Inc. Presents at Second Annual...

2022-04-21 13:00:00

Myriad Genetics, Inc. Presents at Second Annual Canine Health Summit 2022, Apr-27-2022 . Speakers: Jerry Lanchbury, Chief Science Officer.

Neutral

Myriad Genetics, Inc., Annual General Meeting, ...

2022-04-14 20:06:00

Myriad Genetics, Inc., Annual General Meeting, Jun 02, 2022, at 08:00 Mountain Daylight. Agenda: To elect three Class II directors to the Boar...

Neutral

Myriad Genetics, Inc. - Shareholder/Analyst Call

2022-04-14 20:06:00

Annual Meeting of Stockholders

Negative

Myriad Genetics, Inc. Settles the Qui Tam Lawsu...

2022-04-01 20:23:00

On April 1, 2022, Myriad Genetics, Inc. settled the qui tam lawsuit that was filed by STF, LLC against Crescendo Bioscience, LLC (formerly kno...

Neutral

Myriad Genetics, Inc. Presents at Bank of Ameri...

2022-03-22 05:03:00

Myriad Genetics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 11:20 AM. Venue: Encore Hotel, 3121 Las Vegas Blvd. ...

Neutral

Tranche Update on Myriad Genetics, Inc. (Nasdaq...

2022-02-25 16:58:00

From October 1, 2021 to December 31, 2021, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has co...

Neutral

Bank of America Corporation, Bank of America 20...

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vega...

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43...

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Reso...

Negative

Myriad Genetics, Inc. Announces Retirement of C...

2022-01-04 21:47:00

Myriad Genetics, Inc. announced the retirement of Jerry Lanchbury Ph.D. as chief scientific officer (CSO), after more than 19 years of disting...

Negative

Myriad Genetics Promotes Nicole Lambert to Chie...

2021-12-14 21:05:00

Myriad Genetics, Inc. announced the promotion of Nicole Lambert to chief operating officer (COO). In her new role, she will continue to repor...

Neutral

Myriad Genetics, Inc. Presents at 2021 San Anto...

2021-11-22 12:05:00

Myriad Genetics, Inc. Presents at 2021 San Antonio Breast Cancer Symposium, Dec-07-2021 through Dec-10-2021. Venue: San Antonio, Texas, United...

Neutral

The University of Texas Health Science Center a...

2021-11-19 14:00:00

The University of Texas Health Science Center at San Antonio, 2021 San Antonio Breast Cancer Symposium, Dec 07, 2021 through Dec 10, 2021. Ven...

Positive

Myriad Genetics to Seek Acquisitions

2021-11-02 20:30:00

Myriad Genetics, Inc. (NasdaqGS:MYGN) will look for acquisitions. Paul Diaz President and Chief Executive Officer said, “Our transformation pl...

Neutral

Myriad Genetics, Inc. Not Provides Financial Gu...

2021-11-02 12:41:00

Given the continued unpredictability surrounding the COVID-19 pandemic (and its variant strains) as well as the impact it continues to have on...

Neutral

Myriad Genetics, Inc. to Report Q3, 2021 Result...

2021-10-27 21:05:00

Myriad Genetics, Inc. announced that they will report Q3, 2021 results Pre-Market on Nov 02, 2021

Neutral

Myriad Genetics, Inc., Q3 2021 Earnings Call, N...

2021-10-27 21:05:00

Myriad Genetics, Inc., Q3 2021 Earnings Call, Nov 02, 2021

Negative

Myriad Genetics Names Pamela Wong as Chief Lega...

2021-10-18 11:05:00

Myriad Genetics, Inc. announced the appointment of Pamela Wong as its new Chief Legal Officer. In her role, she is responsible for leading the...

Neutral

Ridgeview Institute Elevates Standard of Care i...

2021-10-05 13:00:00

Ridgeview Institute is modernizing the standard of care for behavioral health treatment for Georgians in need of mental health and addiction s...

Positive

Laboratory Corporation of America Holdings (NYS...

2021-09-13 00:00:00

Laboratory Corporation of America Holdings (NYSE:LH) entered into a definitive agreement to acquire Autoimmune’s Vectra Testing Business from ...

Neutral

Myriad Genetics, Inc. Presents at European Soci...

2021-08-23 12:06:00

Myriad Genetics, Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021 . Venue: Paris Expo Porte de Versai...

Neutral

Tranche Update on Myriad Genetics, Inc. (Nasdaq...

2021-08-04 16:07:00

From April 1, 2021 to June 30, 2021, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has complete...

Negative

Myriad Genetics, Inc. Reports Goodwill and Long...

2021-08-03 11:05:00

Myriad Genetics, Inc. reported goodwill and long-lived asset impairment charges for the second quarter ended June 30, 2021. For the period, th...

Positive

Myriad Genetics, Inc. Launches New Version of i...

2021-08-02 11:05:00

Myriad Genetics, Inc. launched a new version of its MyRisk Hereditary Cancer Test. For the first time, women of all ancestries can now receive...

Neutral

Myriad Genetics, Inc., Q2 2021 Earnings Call, A...

2021-07-28 20:05:00

Myriad Genetics, Inc., Q2 2021 Earnings Call, Aug 03, 2021

Neutral

Myriad Genetics, Inc. to Report Q2, 2021 Result...

2021-07-28 20:05:00

Myriad Genetics, Inc. announced that they will report Q2, 2021 results Pre-Market on Aug 03, 2021

Positive

Q2 Solutions LLC completed the acquisition of M...

2021-07-01 00:00:00

Q2 Solutions LLC signed a definitive agreement to acquire Myriad RBM, Inc. from Myriad Genetics, Inc. (NasdaqGS:MYGN) for approximately $200 m...

Neutral

Myriad Genetics, Inc. Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration

2022-06-23 20:05:00

Myriad Genetics, Inc. announced a partnership with Epic to integrate Myriad’s full line of genetic tests with Epic’s expansive network of 600,000 physicians and more than 250 million patients. The integration creates a seamless, end-to-end workflow solution for healthcare providers to order Myriad tests and review results directly within their everyday Epic platform without additional steps or manual ordering processes. Epic enables a secure exchange of information between healthcare institutions that care for patients. With the ability to review pertinent health information, order tests, and receive results natively in Epic, providers will have the critical genetic insights and related information they need to drive better health outcomes and improve the patient experience. Patients will also be able to easily access their Myriad test results and other health information directly within their EHR portal. As part of its transformation and growth plan, Myriad is focusing on new customer-centric, tech-enabled tools to make the genetic testing process easier for patients and clinicians. With the recent launch of Myriad’s Precise Oncology Solutions, providers can now place a single order for multiple Myriad tests and receive timely results through a unified online portal. Now, through the partnership with Epic, Myriad is expanding efforts to help physicians and health systems gain access to genetic testing faster and conveniently within the platform they use every day. Myriad’s integration with Epic is expected to go live later this year.

Neutral

Myriad Genetics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022 01:20 PM

2022-06-10 00:52:00

Myriad Genetics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022 01:20 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Paul J. Diaz, CEO, President & Director.

Neutral

Myriad Genetics, Inc. has filed a Shelf Registration in the amount of $37.44 million.

2022-06-06 00:00:00

Myriad Genetics, Inc. has filed a Shelf Registration in the amount of $37.44 million. Security Name: Common Stock Securities Offered: 2,000,000 Transaction Features: ESOP Related Offering

Negative

Myriad Genetics, Inc. Announces Executive Changes

2022-06-02 20:30:00

On June 2, 2022, the Board of Directors of Myriad Genetics, Inc. designated Natalie Munk, the Company's Chief Accounting Officer, to serve as the Company's principal accounting officer. Ms. Munk will assume responsibility as principal accounting officer from R. Bryan Riggsbee, who will continue his role as the Company's Chief Financial Officer and principal financial officer.

Positive

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

2022-05-26 22:30:00

Myriad Genetics, Inc. will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the value of genetic insights to guide and clarify cancer treatment and risk assessment. The presentations underscore Myriad’s commitment to partnering with oncologists and other healthcare partners to support health equity and provide data-driven insights to help guide clinical care and improve outcomes. They follow the recent launch of Precise™ Oncology Solutions, a comprehensive suite of solutions offering germline testing, tumor profiling, and companion diagnostic options, including evaluation for homologous recombination deficiency (HRD). The suite offers a streamlined testing experience designed to help oncologists recommend personalized treatment plans for their patients.

Neutral

Myriad Genetics, Inc. Provides Earnings Guidance for the Fiscal Year 2022

2022-05-05 13:00:00

Myriad Genetics, Inc. provided earnings guidance for the fiscal year 2022. For the year, the company expects revenue to be in the range of $670 million to $700 million and GAAP LPS to be in the range of $0.90 to $0.70.

Negative

Myriad Genetics, Inc. Reports Goodwill and Long-Lived Asset Impairment Charges for the First Quarter Ended March 31, 2022

2022-05-05 13:00:00

Myriad Genetics, Inc. reported goodwill and long-lived asset impairment charges for the first quarter ended March 31, 2022. For the quarter, the company reported Goodwill and long-lived asset impairment charges of $10.7 million.

Neutral

Myriad Genetics, Inc. Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise Oncology Solutions

2022-05-03 20:15:00

Myriad Genetics, Inc. announced the expansion of its strategic partnership with Intermountain Precision Genomics to add a new liquid biopsy therapy selection test to its growing oncology portfolio. Compared to standard tissue biopsies, many oncologists prefer liquid biopsy testing to analyze traces of tumor DNA in the blood, providing an often quicker, less invasive alternative for cancer treatment selection. For many patients, liquid biopsy is necessary when tissue sampling is not feasible. Liquid biopsy therapy selection testing can be used to support the care of all patients with advanced cancer. Given Myriad’s leading capabilities in hereditary and tumor testing for breast, ovarian, prostate, and pancreatic cancer, the company anticipates initial utilization of its new liquid biopsy offering in these key indications. The collaboration and platform established for Myriad’s recently launched Precise™ Tumor Molecular Profile Test leverages the strengths of Myriad’s hereditary cancer and companion diagnostic tests with Intermountain’s world-class laboratory services. Intermountain performs Precise Tumor testing as part of the Precise Oncology Solutions offering and will add the TruSight™ Oncology 500 ctDNA assay from Illumina to support liquid biopsy therapy selection testing. This further strengthens Myriad’s ability to partner with leading pharmaceutical companies in the near term, supporting its companion diagnostic business and positioning the company for additional commercial growth opportunities. Myriad’s liquid biopsy therapy selection test will be part of its Precise Oncology Solutions – a comprehensive suite of solutions that offers germline testing, tumor profiling and companion diagnostics. Oncologists prefer the single ordering experience and easy-to-interpret summary findings the Precise suite provides to help quickly determine personalized treatment for patients. The suite currently includes Myriad’s Precise Tumor Test, MyRisk™ Hereditary Cancer Test and its two FDA-approved companion diagnostics, MyChoice® CDx and BRACAnalysis CDx®.

Neutral

Myriad Genetics, Inc. to Report Q1, 2022 Results on May 05, 2022

2022-04-28 20:05:00

Myriad Genetics, Inc. announced that they will report Q1, 2022 results Pre-Market on May 05, 2022

Neutral

Myriad Genetics, Inc., Q1 2022 Earnings Call, May 05, 2022

2022-04-28 20:05:00

Myriad Genetics, Inc., Q1 2022 Earnings Call, May 05, 2022

Neutral

Embark Veterinary, Inc., Second Annual Canine Health Summit 2022, Apr 27, 2022 through Apr 28, 2022

2022-04-21 13:00:00

Embark Veterinary, Inc., Second Annual Canine Health Summit 2022, Apr 27, 2022 through Apr 28, 2022.

Neutral

Myriad Genetics, Inc. Presents at Second Annual Canine Health Summit 2022, Apr-27-2022

2022-04-21 13:00:00

Myriad Genetics, Inc. Presents at Second Annual Canine Health Summit 2022, Apr-27-2022 . Speakers: Jerry Lanchbury, Chief Science Officer.

Neutral

Myriad Genetics, Inc., Annual General Meeting, Jun 02, 2022

2022-04-14 20:06:00

Myriad Genetics, Inc., Annual General Meeting, Jun 02, 2022, at 08:00 Mountain Daylight. Agenda: To elect three Class II directors to the Board of Directors to serve until the 2025 Annual Meeting of Stockholders;to ratify the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022;to approve, on an advisory basis, the compensation of named executive officers, as disclosed in this proxy statement;to approve Amended and Restated 2012 Employee Stock Purchase Plan; and to transact such other business that is properly presented at the Annual Meeting and any adjournments or postponements thereof.

Neutral

Myriad Genetics, Inc. - Shareholder/Analyst Call

2022-04-14 20:06:00

Annual Meeting of Stockholders

Negative

Myriad Genetics, Inc. Settles the Qui Tam Lawsuit with STF, LLC

2022-04-01 20:23:00

On April 1, 2022, Myriad Genetics, Inc. settled the qui tam lawsuit that was filed by STF, LLC against Crescendo Bioscience, LLC (formerly known as Crescendo Bioscience, Inc.), a wholly owned subsidiary of the Company (Crescendo" and together with the Company, the Defendants"), and the Company, which is currently pending in the United States District Court for the Northern District of California. The Relator filed the qui tam lawsuit in April 2016 alleging claims concerning Crescendo's former test, Vectra, and conduct dating back to 2010, under the federal False Claims Act, the California False Claims Act, and the California Insurance Fraud Protection Act (the CIFPA"). After conducting an investigation of the allegations, in January 2020, the United States Department of Justice declined to intervene in the lawsuit. Also, in January 2020, the State of California declined to intervene. Pursuant to the terms of the settlement agreements, the Company has agreed to pay a total of $45.25 million to the United States and the State of California and $2.75 million to Relator's counsel. The Relator has agreed to the dismissal of the lawsuit with prejudice as to the Relator and fully releases all claims against the Defendants and their affiliates, directors, officers, and employees. The State of California has agreed to the dismissal of the lawsuit with prejudice as to the State of California and releases the Defendants from any claims submitted to the State's Medicaid program or under the CIFPA as a result of certain alleged conduct. The United States Department of Justice has approved the settlement of federal claims, including dismissal of the lawsuit without prejudice as to the United States. The settlement agreements contain no admission of liability, wrongdoing or responsibility on the part of the Defendants. The Company expressly denies any and all liability for claims alleged in the lawsuit.

Neutral

Myriad Genetics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 11:20 AM

2022-03-22 05:03:00

Myriad Genetics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 11:20 AM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Paul J. Diaz, CEO, President & Director.

Neutral

Tranche Update on Myriad Genetics, Inc. (NasdaqGS:MYGN)'s Equity Buyback Plan announced on November 5, 2013.

2022-02-25 16:58:00

From October 1, 2021 to December 31, 2021, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 18,227,779 shares, representing 25.26% for $588.23 million under the buyback announced on November 5, 2013.

Neutral

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Negative

Myriad Genetics, Inc. Announces Retirement of Chief Scientific Officer Jerry Lanchbury

2022-01-04 21:47:00

Myriad Genetics, Inc. announced the retirement of Jerry Lanchbury Ph.D. as chief scientific officer (CSO), after more than 19 years of distinguished service. Most recently, he drove health equity advancements such as Myriad’s MyRisk™ Hereditary Cancer Test with RiskScore® for all ancestries.

Negative

Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer

2021-12-14 21:05:00

Myriad Genetics, Inc. announced the promotion of Nicole Lambert to chief operating officer (COO). In her new role, she will continue to report directly to Paul J. Diaz, president and CEO, Myriad Genetics. As COO, she assumes additional responsibility for accelerating the company's transformation and growth plans, elevating products to their full potential, and implementing operational efficiencies to better serve patients and healthcare providers. Prior to her career at Myriad, Lambert served as a genetic counselor at LabCorp.

Neutral

Myriad Genetics, Inc. Presents at 2021 San Antonio Breast Cancer Symposium, Dec-07-2021 through Dec-10-2021

2021-11-22 12:05:00

Myriad Genetics, Inc. Presents at 2021 San Antonio Breast Cancer Symposium, Dec-07-2021 through Dec-10-2021. Venue: San Antonio, Texas, United States. Presentation Date & Speakers: Dec-08-2021, Elisha Hughes. Dec-10-2021, Kirsten Timms.

Neutral

The University of Texas Health Science Center at San Antonio, 2021 San Antonio Breast Cancer Symposium, Dec 07, 2021 through Dec 10, 2021

2021-11-19 14:00:00

The University of Texas Health Science Center at San Antonio, 2021 San Antonio Breast Cancer Symposium, Dec 07, 2021 through Dec 10, 2021. Venue: San Antonio, Texas, United States.

Positive

Myriad Genetics to Seek Acquisitions

2021-11-02 20:30:00

Myriad Genetics, Inc. (NasdaqGS:MYGN) will look for acquisitions. Paul Diaz President and Chief Executive Officer said, “Our transformation plan is progressing as expected, although there remains to be a great deal of work to be done. We have successfully reset our base of operations and refocus our organization to reduce complexity and cost and better serve our customers. We are now turning our attention to accelerating growth by investing in innovation and technology, including more customer-centric tech-enabled commercial capabilities and strategically sound acquisition opportunities”.

Neutral

Myriad Genetics, Inc. Not Provides Financial Guidance for the Fourth Quarter and Fiscal Year Ending December 31, 2021

2021-11-02 12:41:00

Given the continued unpredictability surrounding the COVID-19 pandemic (and its variant strains) as well as the impact it continues to have on the healthcare environment, customer behavior and the ability to market tests to physicians, Myriad Genetics, Inc. will not provide financial guidance for the fourth quarter ending December 31, 2021 or fiscal year 2021.

Neutral

Myriad Genetics, Inc. to Report Q3, 2021 Results on Nov 02, 2021

2021-10-27 21:05:00

Myriad Genetics, Inc. announced that they will report Q3, 2021 results Pre-Market on Nov 02, 2021

Neutral

Myriad Genetics, Inc., Q3 2021 Earnings Call, Nov 02, 2021

2021-10-27 21:05:00

Myriad Genetics, Inc., Q3 2021 Earnings Call, Nov 02, 2021

Negative

Myriad Genetics Names Pamela Wong as Chief Legal Officer

2021-10-18 11:05:00

Myriad Genetics, Inc. announced the appointment of Pamela Wong as its new Chief Legal Officer. In her role, she is responsible for leading the company’s legal function, including support and counsel for all legal affairs, intellectual property, patent protection, mergers and acquisitions, litigation, regulatory and quality assurance, compliance, and government affairs. As a legal executive and business leader with deep healthcare and legal expertise, Wong brings more than twenty years of experience spanning global IP portfolio development, management and enforcement, risk mitigation and negotiating complex commercial licensing agreements. She will report directly to Paul J. Diaz, president and CEO of Myriad Genetics. Prior to joining Myriad Genetics, Wong spent 14 years with Quest Diagnostics, most recently as its Assistant General Counsel. Prior to Quest, she worked eight years at Baker-McKenzie where she was an intellectual property partner, and at Pillsbury Winthrop Shaw Pittman LLP.

Neutral

Ridgeview Institute Elevates Standard of Care in Behavioral Health Treatment for Georgians Through New Partnership with GeneSight®

2021-10-05 13:00:00

Ridgeview Institute is modernizing the standard of care for behavioral health treatment for Georgians in need of mental health and addiction services, due to a new partnership with GeneSight®. The GeneSight® test, offered through Myriad Genetics, Inc. helps clinicians understand how a particular individual may respond to certain medications by analyzing how a person's genes impact how they may break down or respond to medications commonly prescribed to treat depression, anxiety and other psychiatric conditions. According to the latest federal data, nearly one in five adults in Georgia battle mental illness in any given year, with nearly half a million having at least one major depressive episode. According to one study, fewer than 50% of patients with depression respond to their first prescribed medication, and with each failed medication plan, their response to the treatment may decrease. The process of finding the right medications that work is often frustrating, time-consuming and debilitating.

Positive

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Autoimmune’s Vectra Testing Business from Myriad Genetics, Inc. (NasdaqGS:MYGN).

2021-09-13 00:00:00

Laboratory Corporation of America Holdings (NYSE:LH) entered into a definitive agreement to acquire Autoimmune’s Vectra Testing Business from Myriad Genetics, Inc. (NasdaqGS:MYGN) for approximately $150 million on May 3, 2021. As part of the acquisiton Labcorp will acquire select operating assets and intellectual property (IP) from Myriad Genetics’ autoimmune business unit, including the Vectra® rheumatoid arthritis (RA) assay. The deal is subject to customary closing conditions and regulatory approvals, including under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The transaction is expected to close by the end of the third quarter. Guggenheim Securities, LLC is acting as exclusive financial advisor and Katten Muchin Rosenman LLP is acting as legal advisor to Myriad Genetics. Helen R. Trilling, David E. Thiess, Brooke Bumpers, Scott T. Loughlin, Carin C. Carithers, Leigh Oliver, Lauren E. Battaglia, Michael E. DeLarco, Scott H. Reisch, Susan D. Tiedy-Stevenson, Randy J. Prebula, Aleksander Dukic, T. Clark Weymouth, Lee E. Berner, Jasper Howard, Asmaa Awad-Farid, Jessica A. Bisignano, Michael J. Silver, Allen Hicks, Matthew R. Bowles and Nick Eckstein of of Hogan Lovells acted as legal advisor to Labcorp. Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Autoimmune’s Vectra Testing Business from Myriad Genetics, Inc. (NasdaqGS:MYGN) on September 13, 2021.

Neutral

Myriad Genetics, Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021

2021-08-23 12:06:00

Myriad Genetics, Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021 . Venue: Paris Expo Porte de Versailles, Paris, France.

Neutral

Tranche Update on Myriad Genetics, Inc. (NasdaqGS:MYGN)'s Equity Buyback Plan announced on November 5, 2013.

2021-08-04 16:07:00

From April 1, 2021 to June 30, 2021, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 18,227,779 shares, representing 25.26% for $588.23 million under the buyback announced on November 5, 2013.

Negative

Myriad Genetics, Inc. Reports Goodwill and Long-Lived Asset Impairment Charges for the Second Quarter Ended June 30, 2021

2021-08-03 11:05:00

Myriad Genetics, Inc. reported goodwill and long-lived asset impairment charges for the second quarter ended June 30, 2021. For the period, the company reported goodwill and long-lived asset impairment charges of $1.8 million.

Positive

Myriad Genetics, Inc. Launches New Version of its MyRisk Hereditary Cancer Test

2021-08-02 11:05:00

Myriad Genetics, Inc. launched a new version of its MyRisk Hereditary Cancer Test. For the first time, women of all ancestries can now receive a polygenic breast cancer risk assessment together with the market’s most accurate hereditary cancer test. MyRisk with RiskScore offers a breast cancer risk assessment designed to improve patient outcomes and help minimize healthcare disparities. RiskScore results are informed by a combination of genetic markers, clinical and biological variables, personal and family history, and ancestry-specific data. RiskScore is available at no additional cost to women who take the MyRisk test. With traditional hereditary cancer tests, approximately 95% of women will test negative for high-risk gene mutations, but still have additional breast cancer risk factors that need to be managed. The RiskScore component of MyRisk helps women and their physicians assess those added risk factors. An estimated 56% of patients who undergo MyRisk testing and receive a RiskScore result, qualify for medical management changes such as increased cancer surveillance or intervention.

Neutral

Myriad Genetics, Inc., Q2 2021 Earnings Call, Aug 03, 2021

2021-07-28 20:05:00

Myriad Genetics, Inc., Q2 2021 Earnings Call, Aug 03, 2021

Neutral

Myriad Genetics, Inc. to Report Q2, 2021 Results on Aug 03, 2021

2021-07-28 20:05:00

Myriad Genetics, Inc. announced that they will report Q2, 2021 results Pre-Market on Aug 03, 2021

Positive

Q2 Solutions LLC completed the acquisition of Myriad RBM, Inc. from Myriad Genetics, Inc. (NasdaqGS:MYGN).

2021-07-01 00:00:00

Q2 Solutions LLC signed a definitive agreement to acquire Myriad RBM, Inc. from Myriad Genetics, Inc. (NasdaqGS:MYGN) for approximately $200 million on May 21, 2021. The total cash consideration is subject to customary adjustments. The transaction is subject to customary closing conditions. The transaction is expected to close in the third calendar quarter of 2021. Cowen and Company, LLC acted as the financial advisor and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. acted as the legal advisor to Myriad Genetics. Q2 Solutions LLC completed the acquisition of Myriad RBM, Inc. from Myriad Genetics, Inc. (NasdaqGS:MYGN) $197 million on July 1, 2021.

Fundamental Summary

Myriad Genetics's recently released results from Q1 indicate that Myriad Genetics is performing reasonably well and on par with its peers. Its income, value, and income factors all individually appear positive and give support for optimism regarding the likelihood of continued positive performance. We therefore gave Myriad Genetics a total score of 66 out of 100 and a HOLD recommendation.

Myriad Genetics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 164.9 million compared to USD 173.1 million a year ago. Net loss was USD 20.5 million compared to USD 39.5 million a year ago. Basic loss per share from continuing operations was USD 0.26 compared to USD 0.52 a year ago. Diluted loss per share from continuing operations was USD 0.26 compared to USD 0.52 a year ago.

Business Description

Myriad Genetics, a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Sector Overview

Myriad Genetics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Myriad Genetics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 1,255.4 -4.9% 62
Liabilities 305.3 -13.5% 51
Price to Book 1.6 -30.0% 57
Cash & Equivalents 165.2 -36.1% 43
Equity 950.1 -1.8% 51
EBITDA -16.8 61.1% 93
Total Revenues 682.4 -1.2% 89
Parameter Value Change Score
Return on Equity -0.9 69.5% 57
Net Cashflow 16.3 -88.5% 50
Capital Expenditure -17.2 4.4% 82
Asset Turnover 0.5 4.4% 83
Free Cashflow -1.5 -57991.6% 37

* All values are TTM

The below chart reflects Myriad Genetics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Myriad Genetics's peer average final assessment score stands on 69.0, Myriad Genetics's score is 66.

  •  MYGN
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 20 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 22 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 23 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 24 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 26 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 29 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 30 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 31 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 32 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 35 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 36 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 37 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 38 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Myriad Genetics's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Myriad Genetics's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 37.

Bearish 37
Close Price 18.41
52W Low 16.45
52W High 36.66
5D MA 18.55
50D MA 20.16
200D MA 25.77
MACD -0.64
RSI 20.45
STOCH 78.4

Balance Sheet Analysis

Myriad Genetics's recently published balance sheet showed overall, underwhelming numbers. Both Cash & Equivalents and Liabilities were particularly concerning. Myriad Genetics's management did a relatively poor job managing cash and cash equivalents, which now sit at 165.2 and represents a -36.1% change from the last reporting period. This performance is significantly less impressive than its peers and competitors. Consequently, their cash and cash equivalents movement received a grade of 43. Also, In terms of liabilities, Myriad Genetics published uninspiring results. Their reported liabilities were 305.3, representing a -13.5% change from the previous report. This performance is relatively weak in comparison to their peers and suggests that its's stock price will likely suffer until this is solved. Discouraging results like these statistically lead to negative movement in stock prices, so we rated their liabilities movement component 51. That said, one metric, Assets, stood out as strongly positive. Myriad Genetics assets on their balance sheet, moved to 1255.4, which is a -4.9% change from the last period. This performance is interesting in comparison to its peers and competitors. The company's asset component, therefore, received a grade of 62. Consequently, their balance sheet earned a rank of 52.

Parameter Value Change Score
Assets 1,255.4 -4.9% 62
Liabilities 305.3 -13.5% 51
Price to Book 1.6 -30.0% 57
Cash & Equivalents 165.2 -36.1% 43
Equity 950.1 -1.8% 51
* All values are TTM

The below chart describes Myriad Genetics's performance as reflected on its balance sheet with respect to its peers. While Myriad Genetics received a balance sheet score of 52, the average of its peers stands on 69.0.

  •  MYGN
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 20 1
Natera, Inc. 3.6B 73 65 43 95 42 54 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 22 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 23 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 24 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 26 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 29 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 30 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 31 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 32 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 33 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 35 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 36 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 37 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 38 1
Geron Corporation 566.2M 69 72 37 59 62 60 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Myriad Genetics's income statement showed strong financials, specifically EBITDA and Revenue Efficiency. Myriad Genetics's management did a remarkable job this period managing its EBITDA. In terms of the raw numbers, EBITDA was reported as -16.8, which represents a 61.1% change from the last period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Its EBITDA metrics highlight an impressive overall financial performance, which is expected to continue moving forward. Consequently, their EBITDA movement received a grade of 93. Also, Myriad Genetics reported highly encouraging numbers for its revenue efficiency. This characteristic can affect companies in the same industry and market capitalization by up to 13.1%. Their industry-leading revenue efficiency makes a strong case for upward pressure on its's stock price. The company's revenue efficiency, therefore, received a grade of 89. However, one discouraging result, Return Factors, stood out. In this filing, Myriad Genetics reported a return on equity (ROE) ratio of -0.9, which represents a growth of 69.5%. This metric might have a 3.6 percent impact on companies in the same industry and with the same market capitalization. These numbers show that management has been unsuccessful in fostering appropriate growth related to return on assets and return on equity momentum relative to their peers. Consequently, their return factors received a grade of 57. Because its management is doing an excellent job managing these critical metrics, the income statement was given a score of 96.

Parameter Value Change Score
EBITDA -16.8 61.1% 93
Total Revenues 682.4 -1.2% 89
Return on Equity -0.9 69.5% 57
* All values are TTM

The below chart describes Myriad Genetics's performance as reflected on its income statement with respect to its peers. While Myriad Genetics received a income statement score of 96 , the average of its peers stands on 67.0.

  •  MYGN
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 20 1
Natera, Inc. 3.6B 52 51 78 52 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 22 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 23 1
Insmed Incorporated 2.4B 51 58 73 57 24 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 26 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 28 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 29 1
IVERIC bio, Inc. 1.1B 84 58 79 70 30 1
FibroGen, Inc. 1.0B 48 74 63 67 31 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 32 1
ImmunoGen, Inc. 946.1M 40 73 71 64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 35 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 36 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 37 1
AnaptysBio, Inc. 586.3M 97 50 77 68 38 1
Geron Corporation 566.2M 89 67 73 78 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Myriad Genetics's recently published cash flow conveys disappointing growth, particularly with respect to Free Cash flow and Net Cash Flow metrics. Myriad Genetics's published free cash flow numbers were subpar and could mean that management has lost focus on achieving healthy growth. Myriad Genetics recorded free cash flow of -1.5, which represents -57991.6% growth from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. Their free cash flow situation is more concerning relative to their peers and competitors. Disappointing results in free cash flow often lead to negative pressure in stock prices, so we rated their free cash flow with a score of 37. Also, Myriad Genetics's management was not successful in meaningfully improving their cash flow metrics. As of the current filing, they were reported as 16.3 and represented a -88.5% change from the previous period. Their net cash flow momentum should be a cause for concern and could bring negative momentum for Myriad Genetics's stock price going forward. Hence, their net cash flow earned a score of 50. At the same time, one {cash_flow} metric, Asset Turnover, was actually strongly positive. Myriad Genetics's published asset turnover numbers were encouraging and reflected management's balanced change strategy. Myriad Genetics recorded asset turnover of 0.5, which represents a 4.4% change from the previous report. This metric might have a 4.1 percent impact on companies in the same industry and with the same market capitalization. Their asset turnover numbers are significantly more impressive when contrasted against their peers and competitors. Correspondingly, their asset turnover movement received a grade of 83. Therefore, its cash flow earned a grade of 59.

Parameter Value Change Score
Net Cashflow 16.3 -88.5% 50
Capital Expenditure -17.2 4.4% 82
Asset Turnover 0.5 4.4% 83
Free Cashflow -1.5 -57991.6% 37
* All values are TTM

The below chart describes Myriad Genetics's performance as reflected on its cash flow with respect to its peers. While Myriad Genetics received a cash flow score of 59, the average of its peers stands on 70.0.

  •  MYGN
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 20 1
Natera, Inc. 3.6B 52 54 56 84 58 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 22 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 23 1
Insmed Incorporated 2.4B 79 80 61 89 82 24 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 26 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 28 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 29 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 30 1
FibroGen, Inc. 1.0B 86 74 48 87 84 31 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 32 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 33 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 35 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 36 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 37 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 38 1
Geron Corporation 566.2M 78 68 49 81 77 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.